Delving into the Latest Updates on Immtech Pharmaceuticals, Inc. with Synapse

Overview

Iodinated forms of C-reactive protein (CRP), soluble modified CRP (mCRP-sol), and suspended mCRP (mCRP-susp) were injected iv into CD-1 mice, for analysis of their pharmacokinetics (PK) and biodistribution (BD). The plasma half-life of 125I-CRP, measured as 4.7 hr, agrees closely with previous reports. The PK and BD characteristics for 125I-mCRP-sol and 125I-mCRP-susp were comparable to each other and were distinctly different from those measured for CRP. Whereas approximately 50% of 125I-CRP was recoverable from plasma 5 min after injection, only approximately 5% of 125I-mCRP was similarly recoverable. The estimated volume of distribution at steady state calculated for either form of 125I-mCRP was approximately 10-fold greater than that calculated for 125I-CRP (23. 4-27.6 and 2.4 ml, respectively). The estimated mean residence times for 125I-mCRP were approximately 2 times longer than that measured for 125I-CRP (9.5-11.5 hr, compared with 4.9 hr). At both 4- and 24-hr time points, substantial amounts of 125I-mCRP were selectively distributed in the bone marrow. At 24 hr, approximately 25% of the injected 125I-mCRP-sol and 125I-mCRP-susp was localized to the bone marrow (corresponding to 92% of injected dose/g of tissue). At this time point, only 8% (or 27%/g) of 125I-CRP was localized to the bone marrow. Overall, the data presented indicate that 1) mCRP has PK and BD characteristics distinct from those of CRP; 2) injected mCRP, although it is rapidly cleared from the general circulation, accesses large body areas and is selectively localized to the bone marrow; and 3) all forms of CRP appear to be excreted in the urine.

1

News (Medical) associated with Immtech Pharmaceuticals, Inc.

15 May 2006

·www.biospace.com

Immtech Pharmaceuticals, Inc. To Present At Rodman & Renshaw 3rd Annual Global Healthcare Conference

VERNON HILLS, Ill., May 12 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. announced today that the Company will be presenting at the Rodman and Renshaw 3rd Annual Global Healthcare Conference to be held at Le Meridien Beach Plaza Hotel, 22, Avenue Princesse Grace, Monte Carlo, Monaco. Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer, will give a corporate update on Tuesday, May 16, 2006 at 10:50 a.m. CEDT. About Immtech Pharmaceuticals Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new treatments for Pneumocystis pneumonia, malaria and African sleeping sickness (Trypanosomiasis), and drug development programs for tuberculosis and fungal infections. The Company has worldwide licensing and exclusive commercialization rights to a large library of well-defined compounds from which a pipeline of therapeutic products could be developed. For additional information, please go to . "Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K for the most recently ended fiscal year. Immtech Pharmaceuticals, Inc. CONTACT: F. C. Thompson, 1-877-898-8038, for Immtech Pharmaceuticals, Inc. Web site:

100 Deals associated with Immtech Pharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Immtech Pharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Jun 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DAP-092	Cryptosporidiosis More	Discontinued
AQ-13	Malaria More	Discontinued
Recombinant modified-C reactive protein(Nextera Therapeutics)	HIV Infections More	Discontinued
Pafuramidine maleate ( Top II )	HIV Infections More	Discontinued
DB-368	Mycoses More	Discontinued